Forbes insight into challenges faced by CGT


Forbes: Though promising, gene therapies face durability and reimbursement headwinds.

Reimbursement plan development will be a key challenge to get Cell & Gene therapies to more patients, extract below:

“Reimbursement of pharmaceutical products generally happens on a per-unit basis, which spreads out costs over years. But, the cost of a gene therapy is much more concentrated, possibly all upfront in a single payment. Such high upfront one-time costs make it harder for payers to underwrite the risk of full payment for one therapy, let alone the entire range of gene therapies that may be coming to market shortly. Therefore, a combination of installment plans and value-based contracting arrangements will likely be the wave of the future for gene therapy reimbursement.”

Full article available here.